Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference
Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company focused on innovative technologies for diagnosing and treating nervous system diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 in New York, NY.
Key points:
- CEO Brad Hauser will present at the conference
- Management will be available for one-on-one meetings with qualified investors
- A video webcast of the presentation will be accessible on-demand from September 9, 2024, at 7:00 AM ET
- The webcast will be available on the Company's website for 90 days following the event
This presentation offers an opportunity for investors to gain insights into Autonomix's innovative medical technologies and future prospects.
Autonomix Medical, Inc. (NASDAQ: AMIX), un'azienda di dispositivi medici focalizzata su tecnologie innovative per diagnosticare e trattare le malattie del sistema nervoso, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. L'evento si svolgerà dal 9 all'11 settembre 2024 a New York, NY.
Punti chiave:
- Il CEO Brad Hauser presenterà alla conferenza
- La direzione sarà disponibile per incontri one-to-one con investitori qualificati
- Un webcast video della presentazione sarà accessibile on-demand a partire da 9 settembre 2024, alle 7:00 AM ET
- Il webcast sarà disponibile sul sito web dell'azienda per 90 giorni dopo l'evento
Questa presentazione offre un'opportunità per gli investitori di ottenere informazioni sulle tecnologie mediche innovative di Autonomix e sulle prospettive future.
Autonomix Medical, Inc. (NASDAQ: AMIX), una empresa de dispositivos médicos centrada en tecnologías innovadoras para diagnosticar y tratar enfermedades del sistema nervioso, ha anunciado su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright. El evento se llevará a cabo del 9 al 11 de septiembre de 2024 en Nueva York, NY.
Puntos clave:
- El CEO Brad Hauser presentará en la conferencia
- La dirección estará disponible para reuniones individuales con inversores calificados
- Una transmisión en video de la presentación estará disponible bajo demanda a partir del 9 de septiembre de 2024, a las 7:00 AM ET
- La transmisión estará disponible en el sitio web de la empresa durante 90 días después del evento
Esta presentación ofrece una oportunidad para que los inversores obtengan información sobre las tecnologías médicas innovadoras de Autonomix y las perspectivas futuras.
Autonomix Medical, Inc. (NASDAQ: AMIX), 혁신적인 기술을 통해 신경계 질환을 진단하고 치료하는 데 중점을 둔 의료 기기 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 이벤트는 2024년 9월 9일부터 11일까지 뉴욕에서 개최됩니다.
주요 내용:
- CEO 브래드 하우저가 컨퍼런스에서 발표할 예정입니다.
- 경영진은 자격이 있는 투자자와 일대일 회의를 가질 수 있습니다.
- 발표의 비디오 웹캐스트는 2024년 9월 9일 오전 7시 ET부터 주문형으로 이용할 수 있습니다.
- 웹캐스트는 이벤트 종료 후 회사 웹사이트에서 90일간 제공될 것입니다.
이번 발표는 투자자들에게 Autonomix의 혁신적인 의료 기술과 미래 전망에 대한 통찰을 얻을 수 있는 기회를 제공합니다.
Autonomix Medical, Inc. (NASDAQ: AMIX), une entreprise de dispositifs médicaux axée sur des technologies innovantes pour diagnostiquer et traiter les maladies du système nerveux, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'événement se déroulera du 9 au 11 septembre 2024 à New York, NY.
Points clés :
- Le PDG Brad Hauser présentera à la conférence
- La direction sera disponible pour des réunions individuelles avec des investisseurs qualifiés
- Un webinaire vidéo de la présentation sera accessible à la demande à partir du 9 septembre 2024 à 7h00 ET
- Le webinaire sera disponible sur le site web de l'entreprise pendant 90 jours après l'événement
Cette présentation offre une opportunité aux investisseurs d'acquérir des informations sur les technologies médicales innovantes d'Autonomix et ses perspectives d'avenir.
Autonomix Medical, Inc. (NASDAQ: AMIX), ein Medizintechnikunternehmen, das sich auf innovative Technologien zur Diagnose und Behandlung von Erkrankungen des Nervensystems spezialisiert hat, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt. Die Veranstaltung findet vom 9. bis 11. September 2024 in New York, NY, statt.
Wichtige Punkte:
- CEO Brad Hauser wird auf der Konferenz präsentieren
- Das Management steht für persönliche Treffen mit qualifizierten Investoren zur Verfügung
- Ein Video-Webcast der Präsentation wird ab 9. September 2024, 7:00 Uhr ET auf Abruf verfügbar sein
- Der Webcast wird 90 Tage lang nach der Veranstaltung auf der Website des Unternehmens verfügbar sein
Diese Präsentation bietet Investoren die Möglichkeit, Einblicke in die innovativen Medizintechnologien von Autonomix und deren zukünftige Perspektiven zu gewinnen.
- None.
- None.
THE WOODLANDS, TX, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 9, 2024, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website (autonomix.com). The webcast replay will be archived for 90 days following the event.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com
FAQ
When is Autonomix Medical (AMIX) presenting at the H.C. Wainwright Global Investment Conference?
Who will be representing Autonomix Medical (AMIX) at the H.C. Wainwright conference?
How can investors access the Autonomix Medical (AMIX) presentation from the H.C. Wainwright conference?
How long will the webcast of Autonomix Medical's (AMIX) presentation be available?
What is the focus of Autonomix Medical (AMIX) as a company?
